Debbie Rigby takes a look at the latest in research news
The aim of this review is to discuss the safety issues that need to be considered with medicinal cannabis. Medicinal cannabis is generally well tolerated when prescribed at appropriate doses; CBD has fewer safety concerns than THC. For patients taking concomitant medications, it is important to carefully monitor for dose-related side effects and consider therapeutic blood monitoring for drugs with a narrow therapeutic window.
Australian Journal of General Practice 2021;50(6):345-50.
This article provides an overview of what is known about medicinal cannabis as a treatment for paediatric developmental disorders. Observational studies have reported symptomatic benefits from CBD-rich products in autism. However, the authors recommend that CBD-rich medicinal cannabis should be prescribed judiciously.
Australian Journal of General Practice 2021;50(6):352-5.
Nearly 2% of Australian adults have both type 2 diabetes and cardiovascular disease. Optimising appropriate treatment with BP-lowering and lipid-modifying medicines are known to reduce cardiovascular events in people with diabetes and CVD. Analysis of Medicineinsight data shows potential room for improvement in prescribing of recommended medicines, risk factor monitoring and achievement of general guideline-recommended targets.
Australian Journal of General Practice 2021;50(4);238-45.
A Cochrane review of 23 studies (n=2872) has concluded the effects of GORD treatment among people with asthma remain uncertain. Medical treatment for GORD in people with asthma may provide small benefit for a number of secondary outcomes related to asthma management, such as improved lung function and reduced use of rescue medications.
Cochrane Database of Systematic Reviews 2021, Issue 5.